SCHEMBL30557698

SCHEMBL30557698

Cc1cc(Cc2ccc(-c3ccccc3)cc2)c(C)s1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
COMT P21964 1/20 0.41
TAAR1 Q96RJ0 2/20 0.39
SLC5A2 P31639 3/20 0.39
MPO P05164 1/20 0.38
LTA4H P09960 1/20 0.37
PTPN1 P18031 1/20 0.36
HTT P42858 2/20 0.36
ALDH1A1 P00352 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
BCL2 P10415 1/20 0.36
BCL2L1 Q07817 1/20 0.36
CYP19A1 P11511 1/20 0.35
ABCC4 O15439 1/20 0.35
LMNA P02545 1/20 0.35
GAA P10253 1/20 0.35
TSHR P16473 1/20 0.35
PTGS1 P23219 1/20 0.35
IDO1 P14902 1/20 0.35
AGXT P21549 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26784357 0.85 KCNH2 (0.44) TAAR1HTTALDH1A1NPSR1
SCHEMBL30557664 0.80 CYP11B1 (0.35) COMTSLC5A2CYP19A1
SCHEMBL22624611 0.80 KLKB1 (0.35) SLC5A2LTA4HHTTALDH1A1NPSR1
SCHEMBL30516652 0.79 MAPT (0.43) TAAR1HTTALDH1A1LMNA
SCHEMBL30557723 0.76 HSD17B1 (0.42) SLC5A2CYP19A1PTGS1
SCHEMBL30557659 0.75 PSMB5 (0.37)
SCHEMBL13210488 0.75 IDH1 (0.41) TAAR1LTA4HALDH1A1GAAIDO1
SCHEMBL30557622 0.74 BACE1 (0.42) SLC5A2
SCHEMBL11611700 0.74 LTA4H (0.54) TAAR1LTA4HHTTCYP19A1ABCC4
SCHEMBL25367591 0.70 LTA4H (0.42) COMTTAAR1LTA4HHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023158221-A1 PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING ANTICANCER AGENT AND NOVEL COMPOUND HAVING INHIBITORY ACTIVITY WITH RESPECT TO PROSTAGLANDIN E2 RECEPTORS 주식회사 카나프테라퓨틱스 2023-08-24 WO disclosed